LATIN AMERICA ONCOLOGY DEVICE MARKET ANALYSIS

Latin America Oncology Device Market, By Chemotherapy Administration (Gravity Chemotherapy Administration, Syringe Chemotherapy Administration, Pump Chemotherapy Administration, and Others), By Accessories and Consumables (Infusion Sets, Venous Access (Ports, and Needles), Catheter (Central venous catheter(CVC), and Peripherally inserted central catheter(PICC)), Needle Connectors, Syringe Filters, and Software), By Age Group (Pediatric (Infant (from birth to 1 year), Children ( 4 to 10 years), and Teenager/Adolescent (11 to 19 years) and Adults), By End User (Private Hospitals/Clinics (General Hospitals with Oncology Centers, Specialized Hospitals, and Specialized Clinics), Public Hospitals/ Clinics (General Hospitals with Oncology Centers, Specialized Hospitals, and Specialized Clinics), and Others (Homecare Settings, and Research Institutes)), and By Country (Brazil, Mexico, and Chile) -

Published In : Jul 2023
Code : CMI4199
Pages :175
Formats :
Excel and PDF
Industry : Medical Devices

Latin America Oncology Device MarketSize and Trends

Latin America oncology device market is estimated to be valued at US$ 36.60 million in 2023 and is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030).

Latin America Oncology Device Market– Drivers

Commercial tie-ups and acquisitions by key players is expected to drive the market over the forecast period. For instance, in July 2020, Novosanis, a medical device company based in Belgium, announced a distribution partnership with Distribuidora GAP, a Mexica-based enterprising company. As part of this agreement, Distribuidora GAP will sell Novosanis’ Colli-PeeTM, a medical device suited for collection of first void urine, in Mexico. Colli-PeeTM device allows easier and more patient-friendly detection of the human papillomavirus that can lead to cervical cancer.

Increasing awareness about the cancer diagnosis is expected to drive the market over the forecast period. For instance, in January 23 2023, in 2020, the World Health Organization (WHO) set a goal to eliminate cervical cancer as a public health problem globally by 2120. To reach this goal, WHO’s Member States should strive to meet the following interim scale-up targets by 2030: 90% of girls are fully vaccinated with human papillomavirus (HPV) vaccine by 15 years of age; 70% of women are screened using a high-performance test by 35 years of age and again by 45 years of age; 90% of women with pre-cancer are treated, and 90% of women with invasive cancer are managed. To build on the momentum of the global strategy to accelerate the elimination of cervical cancer as a public health problem, a regional cervical cancer elimination strategy has been developed for the WHO Eastern Mediterranean Region that is adapted to the religious, cultural, social, economic, and geographical contexts in the Region.